Title |
Peptide Immunotherapy for Type 1 Diabetes—Clinical Advances
|
---|---|
Published in |
Frontiers in immunology, February 2018
|
DOI | 10.3389/fimmu.2018.00392 |
Pubmed ID | |
Authors |
Emma L. Smith, Mark Peakman |
Abstract |
Autoimmune and allergic diseases occur when an individual mounts an inappropriate immune response to a self-antigen or an innocuous environmental antigen. This triggers a pathogenic T-cell response resulting in damage to specific tissues and organs. In type 1 diabetes (T1D), this manifests as destruction of the insulin-secreting β cells, resulting in a life-long dependency on recombinant insulin. Modulation of the pathogenic T-cell response with antigen-specific peptide immunotherapy offers the potential to restore the immune homeostasis and prevent further tissue destruction. Recent clinical advances with peptide therapy approaches in both T1D and other diseases are beginning to show encouraging results. New technologies targeting the peptides to specific cell types are also moving from pre-clinical development to the clinic. While many challenges remain in clinical development, not least selection of the optimal dose and dosing frequency, this is clearly becoming a very active field of drug development. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 25% |
Unknown | 3 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 93 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 20 | 22% |
Student > Ph. D. Student | 19 | 20% |
Student > Master | 11 | 12% |
Researcher | 9 | 10% |
Other | 7 | 8% |
Other | 5 | 5% |
Unknown | 22 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 15 | 16% |
Biochemistry, Genetics and Molecular Biology | 14 | 15% |
Immunology and Microbiology | 9 | 10% |
Agricultural and Biological Sciences | 7 | 8% |
Chemistry | 6 | 6% |
Other | 18 | 19% |
Unknown | 24 | 26% |